| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Avalo Therapeutics, Inc. (AVTX) has 9 insiders with recent SEC Form 4 filings, including 7 buys and 12 sells. AVTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 275.0K | $5.18M | - | |
| Other | 52.8K | $994.3K | -1,000 | |
| CFO | 17.3K | $326.6K | - | |
| Other | 3.6K | $68.5K | - | |
| Dir | 3.2K | $59.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | Sale+OE | 1,000 | $20.00 | $20,000.00 | -1.9% | - | - | |
| May 28, 2026 | Doyle Mittie | Chief Medical Officer | Sale+OE | 679 | $16.00 | $10,864.00 | -1.4% | - | - | |
| May 6, 2026 | Chan Mitchell | Director | Sell | 3,167 | $22.88 | $72,460.96 | -50.0% | -16.3% | - | |
| Apr 2, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 15,959 | $16.96 | $270,593.02 | -14.4% | -2.6% | - | |
| Apr 1, 2026 | Doyle Mittie | Chief Medical Officer | Sale+OE | 679 | $16.00 | $10,864.00 | -15.8% | +10.7% | - | |
| Nov 14, 2025 | Goldman Jonathan | Director | Sale+OE | 11,367 | $14.33 | $162,936.78 | -100% | -4.7% | - | |
| Nov 13, 2024 | Almenoff June Sherie62 | Director | Buy | 1,000 | $12.75 | $12,749.50 | +200.0% | -42.8% | +9.9% | |
| Jun 27, 2023 | Armistice Capital, LLC56 | 10% Owner | Sell | 3,683,542 | $0.59 | $2,168,897.16 | -60.5% | -62.1% | -87.4% | |
| Jun 26, 2023 | Caissa Capital Management Ltd. | 10% Owner | Buy | 1,608,000 | $0.64 | $1,030,178.81 | -100% | -67.4% | -88.4% | |
| Jun 20, 2023 | Caissa Capital Management Ltd. | 10% Owner | Buy | 8,160 | $3.88 | $31,643.69 | +0.2% | -97.0% | -98.6% |